BMP9 inhibits the growth of breast cancer cells by downregulation of the PI3K/Akt signaling pathway

Li,Shu; Dai,Hongying; He,Yong; Peng,Shusheng; Zhu,Tianjin; Wu,Yang; Li,Chenwei; Wang,Ke

doi:10.3892/or.2018.6572

BMP9 inhibits the growth of breast cancer cells by downregulation of the PI3K/Akt signaling pathway

Authors:
- Shu Li
- Hongying Dai
- Yong He
- Shusheng Peng
- Tianjin Zhu
- Yang Wu
- Chenwei Li
- Ke Wang
View Affiliations

Affiliations: Clinical Laboratory, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, P.R. China, Clinical Laboratory, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, P.R. China, Yubei District People's Hospital of Chongqing, Chongqing 401120, P.R. China
Published online on: July 13, 2018 https://doi.org/10.3892/or.2018.6572
Pages: 1743-1751

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone morphogenetic protein 9 (BMP9) is a member of the BMP family, which is involved in the regulation of tumor biogenesis, development and metastasis. The present study aimed to investigate whether BMP9 inhibits the growth of MDA‑MB‑231 breast cancer cells via the phosphoinositide 3‑kinase (PI3K)/Akt signaling pathway. It was shown that the expression level of BMP9 was significantly decreased, while that of phosphorylated Akt (p‑Akt) was markedly increased in breast cancer tissues compared with these levels in the normal adjacent tissues. An adenovirus overexpressing BMP9 was used to infect the MDA‑MB‑231 cells. The expression level of p‑Akt in the MDA‑MB‑231/BMP9 group was shown to be significantly lower than that in the MDA‑MB‑231/green fluorescent protein (GFP) and MDA‑MB‑231 control groups. The expression levels of cyclins D1, B1 and E1, c‑Myc and matrix metalloproteinase 9 (MMP9) in the MDA‑MB‑231/BMP9 group were also reduced. The generation of a nude mouse xenograft tumor model revealed that the tumor volumes of the MDA‑MB‑231/BMP9 group (0.32±0.05 cm3) was significantly lower compared with that of the MDA‑MB‑231/GFP (1.10±0.05 cm3) and MDA‑MB‑231 (1.12±0.12 cm3) groups, and the expression level of p‑Akt protein in the MDA‑MB‑231/BMP9 group was significantly lower compared with that of the MDA‑MB‑231/GFP and MDA‑MB‑231 groups in the nude mouse xenograft model. Taken together, these results indicate that BMP9 inhibits the growth of MDA‑MB‑231 breast cancer cells by inhibiting the PI3K/Akt signaling pathway both in vivo and in vitro.

View Figures

View References

1	Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J and Qiu F: Expression of CXCR4 and breast cancer prognosis: A systematic review and meta-analysis. BMC Cancer. 14:492014. View Article : Google Scholar : PubMed/NCBI
2	Richards CE, Vellanki SH, Smith YE and Hopkins AM: Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species. Cell Oncol. 41:35–46. 2018. View Article : Google Scholar
3	Chacón RD and Costanzo MV: Triple-negative breast cancer. Breast Cancer Res. 12 Suppl 2:S32010. View Article : Google Scholar
4	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
5	Ma H, Xu X, Clague J, Lu Y, Togawa K, Wang SS, Clarke CA, Lee E, Park HL, Sullivan-Halley J, et al: Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study. Breast Cancer Res. 18:622016. View Article : Google Scholar : PubMed/NCBI
6	Wang K, Feng H, Ren W, Sun X, Luo J, Tang M, Zhou L, Weng Y, He TC and Zhang Y: BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin Oncol. 137:1687–1696. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, et al: Bone morphogenetic protein (BMP) signaling in development and human diseases. Genes Dis. 1:87–105. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ye L, Bokobza SM and Jiang WG: Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (Review). Int J Mol Med. 24:591–597. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wan S, Liu Y, Weng Y, Wang W, Ren W, Fei C, Chen Y, Zhang Z, Wang T, Wang J, et al: BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells. Cell Oncol. 37:363–375. 2014. View Article : Google Scholar
10	García-Álvaro M, Addante A, Roncero C, Fernández M, Fabregat I, Sánchez A and Herrera B: BMP9-induced survival effect in liver tumor cells requires p38MAPK activation. Int J Mol Sci. 16:20431–20448. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lv Z, Wang C, Yuan T, Liu Y, Song T, Liu Y, Chen C, Yang M, Tang Z, Shi Q, et al: Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β-catenin pathway. Oncol Rep. 31:989–994. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ren W, Sun X, Wang K, Feng H, Liu Y, Fei C, Wan S, Wang W, Luo J, Shi Q, et al: BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression. Mol Biol Rep. 41:1373–1383. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ren W, Liu Y, Wan S, Fei C, Wang W, Chen Y, Zhang Z, Wang T, Wang J, Zhou L, et al: BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One. 9:e968162014. View Article : Google Scholar : PubMed/NCBI
14	Zardavas D, Fumagalli D and Loi S: Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: A breakthrough in the management of luminal (ER+/HER2-) breast cancers? Curr Opin Oncol. 24:623–634. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ciruelos Gil EM: Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
16	Grunt TW and Mariani GL: Novel approaches for molecular targeted therapy of breast cancer: Interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 13:188–204. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shimizu T, Kayamori T, Murayama C and Miyamoto A: Bone morphogenetic protein (BMP)-4 and BMP-7 suppress granulosa cell apoptosis via different pathways: BMP-4 via PI3K/PDK-1/Akt and BMP-7 via PI3K/PDK-1/PKC. Biochem Biophys Res Commun. 417:869–873. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wang K, Liu D, Zhu TJ, Tang ZG and Dai HY: BMP9 inhibit the proliferation, invasion and migration of MDA-MB-231 breast cancer cells through binding ALK2 receptor to activate BMPs/SMAD cell signaling pathway. Genomics and Applied Biology. 35:1569–1576. 2016.
20	Bolat Kucukzeybek B, Vedat Bayoglu I, Kucukzeybek Y, Alacacioglu A, Yigit S, Akder Sari A, Akyol M and Oktay Tarhan M: The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer. J BUON. 22:947–952. 2017.PubMed/NCBI
21	Khan S, Brougham CL, Ryan J, Sahrudin A, O'Neill G, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM: JmiR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS One. 8:e687532013. View Article : Google Scholar : PubMed/NCBI
22	Guo X, Connick MC, Vanderhoof J, Ishak MA and Hartley RS: MicroRNA-16 modulates HuR regulation of Cyclin E1 in breast cancer cells. Int J Mol Sci. 16:7112–7132. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Li M, Chen D, Nie J, Xi Y, Yang X, Chen Y and Yang Z: Expression of C-myc and β-catenin and their correlation in triple negative breast cancer. Minerva Med. 108:513–517. 2017.PubMed/NCBI
24	Padala C, Tupurani MA, Puranam K, Gantala S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi RK, Kupsal K, et al: Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One. 12:e01844482017. View Article : Google Scholar : PubMed/NCBI
25	Li B, Yang Y, Jiang S, Ni B, Chen K and Jiang L: Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol. 41:1809–1819. 2012. View Article : Google Scholar : PubMed/NCBI
26	Pal I and Mandal M: PI3K and Akt as molecular targets for cancer therapy: Current clinical outcomes. Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wang Z and Guo J: Mechanical induction of BMP-7 in osteocyte blocks glucocorticoid-induced apoptosis through PI3K/AKT/GSK3β pathway. Cell Biochem Biophys. 67:567–574. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zheng Y, Wang X, Wang H, Yan W, Zhang Q and Chang X: Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway. Tumour Biol. 35:5189–5198. 2014. View Article : Google Scholar : PubMed/NCBI
29	Pancholi S, Lykkesfeldt A, Johnston SRD, Dowsett M and Martin LA: The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. 7 Suppl 2:P2.082005. View Article : Google Scholar :
30	Lin M, Bi H, Yan Y, Huang W, Zhang G, Zhang G, Tang S, Liu Y, Zhang L, Ma J, et al: Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Oncotarget. 8:23436–23447. 2017.PubMed/NCBI
31	Duan L, Ye L, Wu R, Wang H, Li X, Li H, Yuan S, Zha H, Sun H, Zhang Y, et al: Inactivation of the phosphatidylinositol 3-kinase/Akt pathway is involved in BMP9-mediated tumor-suppressive effects in gastric cancer cells. J Cell Biochem. 116:1080–1089. 2015. View Article : Google Scholar : PubMed/NCBI
32	Ye L, Kynaston H and Jiang WG: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res. 6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
33	Dai HY, Xia WY, Zhu TJ, Tang ZG and Wang K: BMP9 inhibits the proliferation of human lung adenocarcinoma A549 cells through BMPs/SMAD signaling pathway. TUMOR. 35:997–1005. 2015.
34	Liu P, Man Y, Wang Y and Bao Y: Mechanism of BMP9 promotes growth of osteosarcoma mediated by the Notch signaling pathway. Oncol Lett. 11:1367–1370. 2016. View Article : Google Scholar : PubMed/NCBI
35	Muñoz-Félix JM, Cuesta C, Perretta-Tejedor N, Subileau M, López-Hernández FJ, López-Novoa JM and Martínez-Salgado C: Identification of bone morphogenetic protein 9 (BMP9) as a novel profibrotic factor in vitro. Cell Signal. 28:1252–1261. 2016. View Article : Google Scholar : PubMed/NCBI
36	Yuan SX, Wang DX, Wu QX, Ren CM, Li Y, Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, et al: BMP9/p38 MAPK is essential for the antiproliferative effect of resveratrol on human colon cancer. Oncol Rep. 35:939–947. 2016. View Article : Google Scholar : PubMed/NCBI
37	Herrera B, van Dinther M, TenDijke P and Inman GJ: Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 69:9254–9262. 2009. View Article : Google Scholar : PubMed/NCBI